| Use of recombinant erythropoietin in treatment of the anemia of prematurity. | |
| | |
MedLine Citation:
|
PMID: 1793163 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The anemia of prematurity is defined by a progressive decline in hemoglobin level occurring over the first 2 months of life. Unlike term newborns whose "physiologic anemia" rarely if ever necessitates any treatment, preterm infants may become anemic enough to have clinical symptoms that indicate a need for red blood cell transfusions. Various factors contribute to the development of this anemia. Some of these factors, such as the short life span of erythrocytes in preterm infants, increased sensitivity of the erythrocytes to oxidative injury, and the blood losses caused by repeated phlebotomies, would normally be expected to induce corrective reticulocytosis. Characteristically, however, this anemia is hyporegenerative. Thus, it is associated with relative reticulocytopenia, low serum erythropoietin levels, and bone marrow erythroid hypoplasia. The recent availability of recombinant human erythropoietin has opened new perspectives in the management of a variety of anemias. Based on current knowledge of the regulation and pathophysiology of fetal and neonatal erythropoiesis, recombinant erythropoietin may represent a logical and efficient alternative to giving red blood cell transfusions in the treatment of the anemia of prematurity. Clinical trials have been initiated in several countries using different approaches and methodology. At this early stage these trials do not yet fully affirm that recombinant erythropoietin can be used as the first-line therapy in infants with the anemia of prematurity. Our own observations, however, suggest that this agent is well tolerated by preterm infants and may exert a corrective effect on the anemia of prematurity. |
| | |
Authors:
|
D S Halpérin |
Related Documents
:
|
2040933 - Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-con... 11275033 - Nucleated red blood cells in meconium aspiration syndrome. 20528363 - Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-r... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: The American journal of pediatric hematology/oncology Volume: 13 ISSN: 0192-8562 ISO Abbreviation: Am J Pediatr Hematol Oncol Publication Date: 1991 |
Date Detail:
|
Created Date: 1992-04-02 Completed Date: 1992-04-02 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7908071 Medline TA: Am J Pediatr Hematol Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 351-63 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, Hôpital cantonal universitaire, Geneva, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia, Neonatal
/
blood,
physiopathology,
therapy* Blood Cell Count / drug effects Blood Transfusion Combined Modality Therapy Drug Evaluation Erythropoiesis Erythropoietin / administration & dosage, physiology, therapeutic use* Hematocrit Humans Immunologic Factors / therapeutic use* Infant, Newborn Infant, Premature / blood Infant, Premature, Diseases / blood, physiopathology, therapy* Injections, Subcutaneous Iron / blood, deficiency Longitudinal Studies Pilot Projects Recombinant Proteins / administration & dosage, therapeutic use Reticulocytes |
| Chemical | |
Reg. No./Substance:
|
0/Immunologic Factors; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 7439-89-6/Iron |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sideroblastic anemia showing unique response to pyridoxine.
Next Document: The GABAergic cerebello-olivary projection in the rat.